Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First

In Waldenström macroglobulinemia (WM), a lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M (IgM) gammopathy, aberrant Bruton tyrosine kinase (BTK) signaling has been identified as one mechanism of pathogenesis. For this reason, selective BTK inhibiting therapies have emerged as...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshpande, Anagha, Munoz, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236432/
https://www.ncbi.nlm.nih.gov/pubmed/35770040
http://dx.doi.org/10.2147/TCRM.S338655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236432/
https://www.ncbi.nlm.nih.gov/pubmed/35770040
http://dx.doi.org/10.2147/TCRM.S338655

Ejemplares similares